Moreover, Amabile et al. [94] showed that 5-azacytidine significantly decreases the malignant potential of BCR-ABL+ cells in a mouse model of CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.